The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Delphi-MD employs direct electrophysiological imaging technology to provide real-time insights into brain network function.

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

Brain disorders like Parkinson's disease (PD) or Alzheimer's disease (AD) start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early ...

Brain disorders like Parkinson’s or Alzheimer’s Disease start to develop in patients much earlier than when their first ...

BENGALURU: Parkinson’s disease (PD) has no cure, and the symptoms get worse as the disease progresses with the patient age.

Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

"For too long, the Parkinson's community has had limited treatment options for advanced disease," Dr. Robert A. Hauser, professor of neurology at the University of South Florida said in a press ...